Tostedt, Germany
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose. There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period. Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.
Phase
3Span
147 weeksSponsor
Celldex TherapeuticsLangenau, Baden-Württemberg
Recruiting
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Phase
3Span
97 weeksSponsor
Alumis IncLangenau
Recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
Phase
3Span
109 weeksSponsor
MoonLake Immunotherapeutics AGLangenau
Recruiting
A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting
Phase
N/ASpan
241 weeksSponsor
AbbVieLangenau
Recruiting
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Phase
3Span
142 weeksSponsor
Janssen Research & Development, LLCLangenau
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
Phase
3Span
197 weeksSponsor
Janssen Research & Development, LLCLangenau
Recruiting
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
Phase
N/ASpan
262 weeksSponsor
SanofiLangenau
Recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Phase
3Span
109 weeksSponsor
Incyte CorporationLangenau
Recruiting
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
Phase
2Span
72 weeksSponsor
Janssen Research & Development, LLCLangenau
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Phase
3Span
201 weeksSponsor
Janssen Research & Development, LLCLangenau
Recruiting